z-logo
open-access-imgOpen Access
Acute Effect of Erythropoietin on Endothelin Release in Uremia
Author(s) -
Ank Nurol,
Adam Bahattin,
Kandemir Tolga,
Tekin Akpolat,
Bedir Abdülkerim
Publication year - 1996
Publication title -
˜the œnephron journals/nephron journals
Language(s) - English
Resource type - Journals
eISSN - 2235-3186
pISSN - 1660-8151
DOI - 10.1159/000188980
Subject(s) - medicine , citation , icon , nephrology , library science , computer science , programming language
Dr. Arik Nurol, Ondokuz Mayis Universitesi, Tip Fakültesi, Nefrologi Bölümü, Kurupelit, TR-55139 Samsun (Turkey) p > 0.05 travenously at a single dose of 75 U/kg. Blood samples for ET-1 determination were taken at 15, 30, and 60 min after injection. Blood pressure readings were recorded simultaneously. Plasma ET-1 levels were measured by the ELISA technique (Amersham, UK). The statistical significance of the alterations in ET-1 concentration and blood pressure readings throughout the study was determined by Friedman two-way ANOVA test. Dear Sir, The correction of anemia by recombi-nant human erythropoietin (rH-Epo) in ure-mic patients may exacerbate hypertension in some hypertensive patients or raises blood pressure in some previously normotensive subjects [1-4]. But the underlying mechanism has not yet been clarified and various causes such as increased blood viscosity and total red cell mass inducing an increase in peripheral resistance [5] and reversal of compensatory vasodilatation induced by renal anemia [6] have been proposed before in several studies. Regarding the pathogenetic factors causing increased systemic vascular resistance during rH-Epo therapy, some other mechanisms such as activation of neurohumoral systems and imbalance of local endothelial factors have been proposed in recent years [7]. Although the presence of some reports suggesting the direct relationship between rH-Epo injection and increased endothelin-1 (ET-1) levels and blood pressure [8-11], a final clear-cut conclusion has not yet been drawn. In order to evaluate the acute effect of rH-Epo injection on ET-1 release in ure-mic patients, we studied plasma ET-1 levels after a single-dose i.v. rH-Epo administration in 10 predialysis patients. We included 10 patients with chronic renal failure, previously untreated by dialysis (mean age 45 years, range 29-58; 6 females, 5 males). The patients had never taken rH-Epo before. After the baseline sampling, rH-Epo (Eprex®‚Cilag, Switzerland) was given in-

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom